A study published in JAMA Ophthalmology (2024) found that individuals using semaglutide had a 4.28-fold increase in the risk of NAION compared to other diabetic medications (Moss et al., 2024)
Our Chief Clinical Officer, Danese, runs through her favorite peptide stack: BPC-157 For healing GHK-Cu For repair IGF-1 LR3 For recovery Were hosting a webinar next Thursday, 10/23, all about peptide therapy
People choose different amounts depending on their comfort and needs
For now, I would not call GLP-1 medicines lupus treatments. Instead, they are promising medicines for weight loss, diabetes, cardiovascular risk reduction, and possibly kidney protection in selected patients
While switching is possible under the guidance of a licensed provider, it requires a careful, personalized strategy to ensure safety and effectiveness
But convenience is only part of the story